Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Practice Management

Hidden Drugs Found in Supplements Promoted for Musculoskeletal Conditions

Diana Ernst, RPh

May 16, 2022

Laboratory analyses revealed certain Artri and Ortiga products contain undeclared drug ingredients.

Indication: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Arrhythmia

Dapagliflozin Reduces CV Death, Heart Failure Worsening in HFpEF Patients

Diana Ernst, RPh

May 9, 2022

The placebo-controlled, event-driven DELIVER study included 6263 patients.

General Medicine

Pfizer, BioNTech Plan to Request EUA Based on Booster Data in 5 to 11 Year-Olds

Diana Ernst, RPh

April 26, 2022

Data from a subanalysis of 30 sera demonstrated that following a third dose, a 36-fold increase in SARS-CoV-2 Omicron neutralizing antibody titers was observed in this age group.

General Medicine

Pfizer-BioNTech COVID-19 Booster Authorized for Teens Aged 16 and 17 Years

Diana Ernst, RPh

December 13, 2021

Individuals in this age group should only receive this vaccine as their booster.

General Medicine

Early Data Suggest Potential Benefit of Heterologous Boosting for COVID-19

Diana Ernst, RPh

December 8, 2021

The independent study conducted by Dan Barouch, MD, PhD, et al of Beth Israel Deaconess Medical Center included a subset of participants from the COV2008 study.

Pulmonary Vasculature

Inhaled Treprostinil Approval Decision Delayed Over Inspection Issue

Diana Ernst, RPh

October 21, 2021

Tyvaso DPI is an investigational drug-device combination therapy that consists of a dry powder formulation of treprostinil and a small, portable, dry powder inhaler.